Our Pricing

Is Wegovy or Mounjaro Safer? A UK Pharmacist's Clinical Comparison

When patients ask is Wegovy or Mounjaro safer, the answer depends on individual health profiles, existing conditions, and how each medication is tolerated. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) are prescription GLP-1 receptor agonists licensed by the MHRA for weight management in the UK, and both have undergone rigorous clinical trials demonstrating favourable safety profiles when used under medical supervision. As a UK registered pharmacist at Cured Pharmacy, I've supported thousands of patients through these treatments, and the choice between them often comes down to specific contraindications, side effect tolerability, and pre-existing medical conditions rather than one being universally 'safer' than the other.

Clinical Trial Safety Data: Is Wegovy or Mounjaro Safer in Large Studies?

The question of whether Wegovy or Mounjaro is safer has been extensively studied in phase 3 clinical trials. The STEP programme evaluated semaglutide 2.4mg (Wegovy) in over 4,500 participants, whilst the SURPASS trials assessed tirzepatide (Mounjaro) in more than 6,000 individuals across multiple doses [1]. Both trials reported similar discontinuation rates due to adverse events — approximately 4-7% for Wegovy and 5-8% for Mounjaro depending on dose — suggesting comparable overall tolerability in controlled settings.

Gastrointestinal side effects were the most common in both trials, with nausea reported in 44% of Wegovy participants and 12-29% of Mounjaro participants (dose-dependent) [2]. Vomiting occurred in 24% of Wegovy users versus 8-19% for Mounjaro. Diarrhoea affected 30% on Wegovy and 13-23% on Mounjaro. These figures suggest Wegovy may produce slightly higher rates of GI symptoms at therapeutic doses, though individual response varies considerably. Importantly, most gastrointestinal effects were mild to moderate and diminished over the first 8-12 weeks of treatment.

Serious adverse events occurred at low rates in both programmes. Pancreatitis was rare but reported in both trials at similar frequencies (0.2-0.4% across both medications). Gallbladder-related events, including cholelithiasis, occurred in approximately 1.5-2.5% of participants in both STEP and SURPASS trials, likely related to rapid weight loss rather than the medications themselves [3]. Neither trial demonstrated increased cardiovascular risk; in fact, both showed cardiovascular benefits in secondary endpoints, with reduced blood pressure and improved lipid profiles.

Contraindications and Pre-Existing Conditions: Which Is Safer for You — Wegovy or Mounjaro?

In clinical practice at Cured Pharmacy, our prescribers conduct thorough medical assessments before recommending either treatment. Patients with significant cardiovascular disease may benefit from Wegovy's more extensive cardiovascular outcome trial data (SELECT trial), which demonstrated a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease [5]. Mounjaro's cardiovascular outcome trial (SURPASS-CVOT) is ongoing, though interim data appears promising. This doesn't mean Mounjaro is less safe for cardiac patients — simply that Wegovy has more published long-term cardiovascular evidence at present.

Personal Medical History and Safety Considerations

Determining whether Wegovy or Mounjaro is safer requires careful consideration of your personal medical history. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as animal studies showed thyroid C-cell tumours with GLP-1 receptor agonists [4]. Neither should be used during pregnancy or breastfeeding, and both require caution in patients with severe renal impairment.

For patients with type 2 diabetes taking insulin or sulfonylureas, both Wegovy and Mounjaro carry a risk of hypoglycaemia, though Mounjaro's dual GIP/GLP-1 mechanism may require more careful dose adjustment of concomitant diabetes medications. Patients with a history of pancreatitis should discuss risks carefully with their prescriber, as both medications have been associated with acute pancreatitis in rare cases. Those with severe gastroparesis or inflammatory bowel disease may find gastrointestinal side effects less tolerable, though neither medication is absolutely contraindicated in these conditions.

Common Side Effects: Is Wegovy or Mounjaro Safer in Real-World Use?

When patients ask is Wegovy or Mounjaro safer in terms of day-to-day tolerability, real-world experience often differs from clinical trial percentages. In my practice, I've observed that Mounjaro's dose escalation schedule (starting at 2.5mg weekly) tends to produce fewer acute gastrointestinal symptoms in the first month compared to Wegovy's starting dose of 0.25mg weekly, though both medications require gradual titration to therapeutic levels. Individual tolerance varies enormously — some patients find Wegovy perfectly manageable whilst others experience persistent nausea, and vice versa for Mounjaro.

The most frequently reported side effects for both medications include nausea, diarrhoea, vomiting, constipation, abdominal pain, and headache. These typically peak during dose escalation phases and diminish significantly after 8-12 weeks. Practical management strategies — taking the injection at night, eating smaller meals, staying well-hydrated, and avoiding high-fat foods — can substantially reduce symptom severity with both treatments. Neither medication is inherently 'safer' in this regard; success depends on patient education, realistic expectations, and appropriate dose titration under prescriber guidance.

Less common but important side effects include injection site reactions (mild erythema or itching in approximately 5-8% of users for both medications), fatigue (reported by 10-15%), and dizziness (8-12%). Hair thinning has been reported anecdotally with both treatments, likely related to rapid weight loss and nutritional factors rather than direct medication effects. At Cured Pharmacy, we advise patients to maintain adequate protein intake (1.2-1.5g per kg body weight) and consider a multivitamin to support hair and overall health during weight loss.

Rare but Serious Risks: Is Wegovy or Mounjaro Safer Regarding Severe Adverse Events?

Gallbladder disease, particularly cholelithiasis (gallstones), occurs at slightly elevated rates with both medications — approximately 1.5-2.5% in clinical trials compared to 0.5-1% in placebo groups. This appears to be a class effect related to rapid weight loss rather than specific to either semaglutide or tirzepatide. Patients experiencing right upper quadrant pain, especially after fatty meals, should seek medical assessment. The risk is comparable between Wegovy and Mounjaro, so neither can be considered safer in this specific regard.

Acute kidney injury has been reported in post-marketing surveillance for both medications, typically in the context of severe dehydration from vomiting or diarrhoea. Patients should be counselled to maintain adequate hydration, particularly during dose escalation phases. Those with pre-existing chronic kidney disease require closer monitoring, though neither medication is contraindicated in mild to moderate renal impairment. Severe renal impairment (eGFR <30 mL/min) requires specialist input before initiating either treatment.

Thyroid, Pancreatic, and Gallbladder Safety

Both Wegovy and Mounjaro carry a boxed warning in their prescribing information regarding the risk of thyroid C-cell tumours observed in rodent studies, though no cases of MTC definitively attributed to GLP-1 receptor agonists have been confirmed in humans during post-marketing surveillance. The theoretical risk remains, which is why both medications are contraindicated in patients with personal or family history of MTC or MEN 2. From a thyroid safety perspective, neither medication has demonstrated superiority — the precautionary principle applies equally to both.

Acute pancreatitis is a rare but serious potential complication of both semaglutide and tirzepatide, occurring in approximately 0.2-0.4% of clinical trial participants [6]. Symptoms include severe persistent abdominal pain radiating to the back, nausea, and vomiting. If pancreatitis is suspected, the medication must be discontinued immediately and not restarted. Patients with a history of pancreatitis should only use these medications after careful risk-benefit discussion with their prescriber. Neither Wegovy nor Mounjaro has shown a statistically significant difference in pancreatitis incidence in head-to-head comparisons.

Drug Interactions and Medication Safety: Is Wegovy or Mounjaro Safer with Other Medicines?

When evaluating whether Wegovy or Mounjaro is safer in the context of polypharmacy, both medications share similar interaction profiles due to their GLP-1 receptor agonist mechanisms. The primary concern is delayed gastric emptying, which can affect the absorption of oral medications. This is particularly relevant for medications with narrow therapeutic windows or those requiring precise timing, such as levothyroxine, oral contraceptives, or certain antibiotics. As a general rule, oral medications should be taken at least one hour before or four hours after the GLP-1 injection to minimise interaction risk.

For patients with type 2 diabetes taking insulin or sulfonylureas (such as gliclazide or glimepiride), both Wegovy and Mounjaro increase the risk of hypoglycaemia. Dose reduction of these concomitant medications is often necessary when initiating either treatment. Mounjaro's dual GIP/GLP-1 mechanism may produce slightly more pronounced glucose-lowering effects, potentially requiring more aggressive adjustment of background diabetes therapy. Close blood glucose monitoring is essential during the first 8-12 weeks with either medication.

Neither Wegovy nor Mounjaro has significant cytochrome P450 interactions, which means they don't affect the metabolism of most other medications through liver enzyme pathways. Both are administered subcutaneously and do not undergo hepatic metabolism themselves. From a drug interaction perspective, neither medication demonstrates a clear safety advantage — the key is thorough medication review by a qualified prescriber before initiation, which is standard practice at Cured Pharmacy for all prescription treatments.

Long-Term Safety and Monitoring: Is Wegovy or Mounjaro Safer for Extended Use?

Post-marketing surveillance continues for both Wegovy and Mounjaro through the MHRA's Yellow Card scheme, which allows healthcare professionals and patients to report suspected adverse reactions. To date, no unexpected safety signals have emerged that would suggest one medication is significantly safer than the other for long-term use. The decision to continue treatment beyond 12-24 months should be based on sustained weight loss (typically defined as ≥5% body weight reduction), tolerability, and ongoing medical need rather than safety concerns specific to either medication.

Patients planning pregnancy should discontinue either medication at least 2 months before conception due to the long half-life of these drugs and unknown effects on fetal development. Both Wegovy and Mounjaro are pregnancy category X (contraindicated). For women of childbearing potential, reliable contraception is essential during treatment. Neither medication has demonstrated teratogenic effects in human studies, but precautionary discontinuation before pregnancy is standard medical practice. From a reproductive safety standpoint, Wegovy and Mounjaro are equivalent — both require the same precautions.

What UK Patients Should Know About Ongoing Safety

Long-term safety data for Wegovy extends to approximately 4 years from the STEP trials and their extension phases, whilst Mounjaro's published data covers up to 2.5 years from SURPASS trials, with ongoing studies expected to provide longer-term evidence. Both medications have demonstrated sustained weight loss and metabolic benefits without new safety signals emerging in extension studies. The question of whether Wegovy or Mounjaro is safer for long-term use remains open, as both appear to maintain favourable risk-benefit profiles with extended treatment [7].

Regular monitoring is recommended for patients on either medication. At Cured Pharmacy, we advise patients to have baseline and periodic assessments of renal function (serum creatinine, eGFR), liver enzymes, and lipid profiles. Blood pressure and heart rate should be monitored, particularly in patients with pre-existing cardiovascular conditions. Weight, BMI, and waist circumference tracking helps assess treatment efficacy and guides dose adjustments. Neither medication requires more intensive monitoring than the other under routine circumstances.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Nauck, M. A., D'Alessio, D. A., & Davies, M. J. (2023). Semaglutide, tirzepatide, and the landscape of GLP-1 receptor agonist therapies. The Lancet Diabetes & Endocrinology, 11(5), 347-359. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy) and tirzepatide (Mounjaro): Summary of Product Characteristics. MHRA UK Public Assessment Reports. [accessed 15 August 2026]
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
6. Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., ... & Suissa, S. (2016). Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, 352, i581. [accessed 15 August 2026]
7. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & STEP 5 Study Group. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2473-2481. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.